|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/506 | (2006.01) |
| A61K 31/401 | (2006.01) | ||
| A61K 38/05 | (2006.01) | ||
| A61K 31/41 | (2006.01) | ||
| A61P 9/12 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61K 31/4035 | (2006.01) |
| (11) | Number of the document | 4014976 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21202979.7 |
| Date of filing the European patent application | 2018-02-26 | |
| (97) | Date of publication of the European application | 2022-06-22 |
| (45) | Date of publication and mention of the grant of the patent | 2024-09-04 |
| (46) | Date of publication of the claims translation | 2024-11-11 |
| (30) | Number | Date | Country code |
| PCT/EP2017/054489 | 2017-02-27 | WO | |
| PCT/EP2017/061487 | 2017-05-12 | WO |
| (72) |
BOLLI, Martin , CH
BELLET, Marc , CH
CLOZEL, Martine , CH
IGLARZ, Marc , CH
|
| (73) |
Idorsia Pharmaceuticals Ltd ,
Hegenheimermattweg 91, 4123 Allschwil,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Aprocitentanas, skirtas panaudoti derinyje su valsartanu, gydant hipertenziją ir su ja susijusias ligas |
| APROCITENTAN FOR USE IN THE TREATMENT OF HYPERTENSION AND RELATED DISEASES IN COMBINATION WITH VALSARTAN |
| Payment date | Validity (years) | Amount | |
| 2026-01-23 | 9 | 208.00 EUR |
| 2027-02-26 |